← Russell 3000 cross-section

AGEN AGENUS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-07, not restated
Healthcare

Scale

Market cap
$361m
Revenue TTM
$133m
Net income TTM
$92m
Free cash flow
$-98m
Composite score
45.4
Sector rank
#2563

Valuation

P / E
3.9
EV / EBITDA
EV / sales
2.8
FCF yield
-27.25%
Earnings yield vs 10-yr
20.70pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
69.3%
EBITDA margin
ROE
-46.2%
ROIC
Revenue growth
30.5%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The collaboration also includes an exclusive license for Zydus to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories, and provides for up to $50.0 million in additional contingent payments tied to BOT and BAL production orders restricted to services provided to us by Zydus. Historical Results of Operations Three months ended June 30, 2026 compared to the three months ended June 30, 2025 Pre-commercial product revenue We recognized pre-commercial product revenue of approximately $6.4 million during the three months ended June 30, 2026, representing sales of BOT/BAL provided to patients through regulatory-au …AGENUS INC, 10-Q, period ended 2026-06-30, filed 2026-08-07

Read the full passage →